Latest News and Press Releases

CRANBURY, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September. Bradley Campbell,...

           2Q19 Galafold® (migalastat) Revenue of $44.1M Represents Highest Quarterly Growth Since Launch Driven by Continued Strong Global Uptake  Reiterating FY19 Revenue Guidance of $160M-$180M ...

         First Oral Precision Medicine Approved for People Living with Fabry Disease with an Amenable Mutation in Argentina First Amicus Regulatory Approval in Latin America CRANBURY, N.J., and...

 Study Shows Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment...

CRANBURY, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2019...

Supports Clinical and Commercial Supply Needs for Pompe and Other Lysosomal Disease Gene Therapy Programs Advances Amicus’ Mission to Deliver Novel Gene Therapies to Rare Disease Patients CRANBURY,...

        Supports Clinical and Commercial Supply Needs for Multiple Batten Disease Programs Advances Amicus Mission to Deliver Novel Gene Therapies to Rare Disease Patients CRANBURY, N.J., July 01,...

Jill Weimer, PhD named Senior Vice President of Discovery Research and Gene Therapy Science Simon Jordan named Senior Vice President of International CRANBURY, N.J., June 13, 2019 (GLOBE...

CRANBURY, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total of...

CRANBURY, N.J., June 03, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following scientific and investor conferences in June. Upcoming...